VIMPAT (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
VIMPAT
Date registered
Evaluation commenced
Decision date
Approval time
250 working days (255)
Active ingredients
lacosamide
Registration type
EOI
Indication
VIMPAT (injection/tablets) is now also indicated as monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older .